Brokers Issue Forecasts for RADX FY2026 Earnings

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) – Investment analysts at Zacks Research issued their FY2026 EPS estimates for Radiopharm Theranostics in a report issued on Tuesday, May 12th. Zacks Research analyst J. Vandermosten expects that the company will earn ($0.01) per share for the year. The consensus estimate for Radiopharm Theranostics’ current full-year earnings is ($2.70) per share. Zacks Research also issued estimates for Radiopharm Theranostics’ FY2027 earnings at ($0.01) EPS.

Radiopharm Theranostics (NASDAQ:RADX) last announced its quarterly earnings data on Wednesday, January 28th. The company reported ($1.58) earnings per share (EPS) for the quarter. The business had revenue of $0.46 million for the quarter.

A number of other equities research analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of Radiopharm Theranostics to a “strong sell” rating in a research note on Friday, January 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Radiopharm Theranostics in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $16.00.

Radiopharm Theranostics Trading Up 4.6%

Shares of Radiopharm Theranostics stock opened at $4.73 on Friday. Radiopharm Theranostics has a 12-month low of $3.62 and a 12-month high of $16.25. The firm’s 50-day moving average price is $4.54 and its two-hundred day moving average price is $4.83.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Marex Group plc bought a new position in shares of Radiopharm Theranostics in the fourth quarter worth about $54,000. Jane Street Group LLC bought a new position in Radiopharm Theranostics in the 4th quarter valued at approximately $76,000. Virtu Financial LLC bought a new position in Radiopharm Theranostics in the 4th quarter valued at approximately $76,000. PNC Financial Services Group Inc. raised its holdings in Radiopharm Theranostics by 100.0% in the 3rd quarter. PNC Financial Services Group Inc. now owns 16,000 shares of the company’s stock valued at $88,000 after buying an additional 8,000 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new position in Radiopharm Theranostics in the 4th quarter valued at approximately $1,007,000.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.